Chief Executive Officer
Ph.D. (Dr.rer.nat.) in recombinant antibody technology. He did his post-doctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany. Born 1961. Lives in Oslo, Norway. Employed since 2018. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech (Nasdaq Copenhagen) and CEO of Opsona Therapeutics, Dublin, Ireland.
Chief Scientific Officer
Doctor of Immunology. Born 1973. Lives in Lund, Sweden. Employed since 2001. Graduated from the Swedish Foundation for Strategic Research funded Biomedicine programmes within the Infection & Vaccinology programme in 2001. Visiting Professor at University of Southampton.
Shareholding: 483,083 (own and affiliated holdings)
Options: Employee options 270,258
Chief Financial Officer
MBA, Lund University. Born 1963. Lives in Lund, Sweden. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. He was employed by the Swedish Tax Authority 1996-1997. Previously he worked as an auditor at PricewaterhouseCoopers 1990-1995.
Options: Employee options 115,825
Chief Medical Officer
Doctor in Medicine and Surgery from the Universidad del Rosario (Bogotá), and holds a PhD from the Pasteur Institut/Université Paris. Born 1956. Lives in Geneva, Switzerland. He has perfomed academic work at the Pasteur Institut and the University of California San Francisco on cancer immunotherapy. Andres joins BioInvent from a position as Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/Pierre Fabre.
Options: Employee options 91,656
Kristoffer Rudenholm Hansson
Senior Vice President, Technical Operations
Master of Science in Chemical engineering. Born 1974. Lives in Malmö Sweden. Employed since 2016 and responsible for process development and production of antibodies for clinical studies. He has more than 15 years’ experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held a numerous positions within CMC Biologics A/S, DAKO A/S and Symphogen A/S.
Shareholding: 491,628 (whereof 148,176 in Sw. kapitalförsäkring)
Options: Subscription warrants 50,000 and employee options 114,059